Abstract. Spinal cord injury (SCI)-induced osteoporosis may cause mild trauma to bone and increase the risk of bone fracture. The present study aimed to investigate the efficacy of coenzyme Q (CoQ10) on SCI-induced osteoporosis in rats. SCI was induced by surgical transection of the cord at the T10-12 level. Animals were treated with CoQ10 (10 mg/kg; intragastrically) daily from 12 h after the surgery and over 10 subsequent days. At the end of the experimental period, blood was collected from the animals and femurs and tibiae were removed for evaluation using biochemical assays. Treatment with CoQ10 prevented SCI-induced bone loss by rescuing the decreased levels of bone mineral density and bone mineral content observed in the SCI rats. Furthermore, CoQ10 administration reduced bone malondialdehyde levels with a concomitant increase in superoxide dismutase levels, thus alleviating SCI-induced oxidative injury. In addition, serum inflammatory cytokine levels were markedly increased in rats post-SCI, which was attenuated by treatment with CoQ10. Finally, the osteoclast-specific genes receptor activator of nuclear factor kappa-B ligand and cathepsin K were significantly upregulated and the osteoblast-specific gene core-binding factor alpha 1 in the femur was downregulated following SCI, which was effectively restored following treatment with CoQ10. The results suggested that CoQ10 treatment may be effective in attenuating SCI-induced osteoporosis.

Introduction

Traumatic spinal cord injury (SCI) is a severe pathological event with consequences which are sustained throughout the life of the patient and eventually cause distress to the family and society (1,2). SCI activates an inflammatory cascade and during this, inflammatory cells from the circulation deteriorate vital organs, including the liver, kidney and lungs (3). Oxidative stress and inflammation may result in post-SCI pathogenesis, including cellular apoptosis, activation of free radicals and enhanced lipid peroxidation (LPO) with subsequent depletion of anti-oxidant agents, and have a pivotal role in SCI-induced secondary organ/tissue damage (4-7). One of the imminent consequences of SCI is a significant bone loss within a few months to a few years of injury (8), leading to fracture in 50% of patients with complete SCI. SCI-induced bone loss generally affects the lower limbs of rats due to longer bones as well as metaphysis, epiphysis and diaphysis of the femur and tibia of rats (9,10). SCI-induced bone loss has significant morbidity and is likely to aggravate already profound disability. Treatment strategies to ameliorate bone loss after SCI by physical methods include passive standing, minimal electrical stimulation and body weight-supported treadmill training (11,12). However, treatment using these strategies has no significant effects. Effective interventions may require targeting of multiple pathways to achieve significant clinical improvement after SCI, and complications including bone loss are warranted. Coenzyme Q10 (CoQ10) is a key mediator of the electron transfer reaction in the respiratory chain in mitochondria. A study suggested that CoQ10 has a free-radical-quenching effect and also displays insulin-like properties in diabetic patients (13). Previous studies provided evidence that CoQ10 has potent anti-oxidant activity (14,15) and protective efficacy in experimental SCI (16). Previous pre-clinical studies demonstrated the anti-osteonecrotic effects (17) and the inhibitory effect on osteoclast differentiation in bone-marrow-derived monocytes and RAW 264.7 cells of CoQ10, which are mediated by its free-radical-scavenging mechanism (18). However, to the best of our knowledge, the effect of CoQ10 in SCI-induced bone loss has not been studied to date. Therefore, the present study was designed to evaluate the therapeutic efficacy of CoQ10 against bone loss induced by SCI in rats.

Materials and methods

Chemicals. Co-enzyme Q10, superoxide dismutase (SOD) and malondialdehyde (MDA) diagnostic kits were obtained from...
Animals. Forty male Sprague-Dawley rats (8 weeks-old, weighing 170-200 g) were obtained from the animal facility at Nanchang University (Nanchang, China). The animals were maintained under standard laboratory conditions of relative humidity (55±5%), temperature (25±2°C), and light (12 h light/dark cycle). They were fed standard diet pellets and water was provided ad libitum. The study was approved by the ethics committee of The First Affiliated Hospital of Nanchang University, (Nanchang, China).

Animal model of SCI. The rats were anesthetized by administration of xylazine + ketamine [10 and 75 mg/kg, respectively; intraperitoneally (i.p.)]. After the dorsum of the animals was shaved and sterilized, an incision was made from the posterior to the lower thoracic region. Laminectomy (thoracic T10-T12 vertebrae) was performed to expose the spinal cord alone (sham group). After the laminectomy, the lower thoracic cord was subsequently completely transected with fine sterilized micro scissors (SCI group) under a magnifier. Both stumps of the spinal cord were gently lifted away to create a 1-2-mm gap, which was filled with sponge gel. The muscle fascia and skin were sutured, and the rats were returned to their cages. After completion of surgery, the animals received a bolus of Lactate Ringers solution (5 ml; i.p.) to compensate for blood loss, and antibiotic cover (systemic gentamycin, 50 mg/kg intramuscularly; local treatment with neosporin ointment) was provided. Furthermore, the SCI rats received daily assistance in bladder emptying until spontaneous miction recovered.

Evaluation of locomotor functions. The quality of locomotion was assessed using the Basso, Beattie, and Bresnahan (BBB) locomotor rating score (19).

Study design. Sprague-Dawley rats were divided into four groups (n=10 each) and treated for 10 days as follows: i) Group I - sham-operated rats (Sham); ii) Group II - SCI rats (SCI); iii) Group III - sham-operated rats receiving CoQ10 (10 mg/kg) intragastrically for 10 days (sham + CoQ10); iv) Group IV - SCI rats receiving CoQ10 (10 mg/kg) for 10 days (SCI + CoQ10).

At the end of the experimental period, rats were fasted overnight and sacrificed by decapitation. Blood was collected in heparinized BD vacutainer (BD Biosciences, San Jose, CA, USA) and serum samples were collected by centrifugation

Preparation of bone homogenate. Frozen bone samples (150 mg) were minced in a phosphate buffer and homogenized in a MagNA Lyser instrument (Roche Applied Science, Penzberg, Germany). Samples were centrifuged three times at 530 x g for 20 sec with intermediate cooling 5 min in the MagNA Lyser Cooling Block. The tissue homogenate was then centrifuged at 10,000 x g at 4°C for 10 min. The supernatant was separated, stored at -80°C and used for further biochemical analysis.
using QuantiTect™ SYBR® Green PCR (Tiangen, Shanghai, China) according to the manufacturer’s instructions. The RT-PCR data were based on SYBR green amplification. The sequences of primers are listed in Table I. The highly specific measurement of mRNA was performed using the Light Cycler system (Bio-Rad Laboratories, Hercules, CA, USA). PCR amplification was performed in 96-well optical reaction plates for 40 cycles, with cycles of 94°C for 30 sec, 58-63°C for 30 sec and 72°C for 60 sec. Each sample was run and analyzed in duplicate. GAPDH mRNA as an internal control was used to normalize the data to determine the relative expression of the target genes. The fold changes relative to values of the sham-operated group were obtained and used to express the changes in gene expression.

Table I. Sequences of oligonucleotides used as primers.

<table>
<thead>
<tr>
<th>Gene (abbreviation)</th>
<th>Gene (full name)</th>
<th>ID</th>
<th>Sequence (5’→3’)</th>
<th>Tm (˚C)</th>
<th>Size (bp)</th>
</tr>
</thead>
</table>
| RANKL               | Receptor activator of nuclear factor-κB ligand | 117516 | Forward: TCAGGAGTTCCA GGATATGAT  
Reverse: CCATCACGCTGAA GATAGTCC | 55 | 298 |
| Cathepsin K         | Cathepsin K      | 29175 | Forward: GAGACATGACGCAGC GAAGAAA  
Reverse: CACATATTGGAAGGC AGTGGG | 56 | 332 |
| Cbfal               | Core binding factor alpha 1 | 367218 | Forward: CGAAATGCCCTCCTGC TGTTAT  
Reverse: TTCTGTCTGTGCCCTT CTTGG | 53 | 194 |
| GAPDH               | Glyceraldehyde 3-phosphate dehydrogenase | 2597 | Forward: ACCACAGTGCCATGCA CATCAC  
Reverse: TCCACCACCTGTGGG CTGTA | 60 | 452 |

Figure 1. Efficacy of CoQ10 on bone strength markers in SCI-induced osteoporotic rats. (A) BMC (g/cm²) and (B) BMDs (in grams). Values are expressed as the mean ± standard deviation for five rats in each group. *P<0.05 for comparisons between *Sham and SCI or *SCI and SCI + CoQ10. SCI, spinal cord injury; BMD, bone mineral density; BMC, bone mineral content; Co, coenzyme.

Results

CoQ10 alleviates decreased BMD and BMC in rats following SCI. The BMD and BMC of femur and tibia were significantly decreased in the SCI group as compared with that in the sham group (P<0.05). Treatment with CoQ10 (10 mg/kg) significantly alleviated the decreasing effect of SCI on BMC (Fig. 1A) and BMD (Fig. 1B) (P<0.05). Treatment of sham-operated rats with CoQ10 had no significant effect on these parameters.

CoQ10 alleviates oxidative stress in bones following SCI. Compared with the sham group, SOD levels in femur and tibia were significantly depleted in SCI rats (P<0.05). However, treatment with CoQ10 effectively restored the SOD status to normal levels (Fig. 2A). Furthermore, MDA, a toxic adduct formed during lipid peroxidation, was significantly elevated
CoQ10 reduces serum inflammatory markers in SCI rats. In the present study, SCI rats displayed a significant elevation of serum inflammatory cytokines IL-6 (Fig. 3) and TNF-α (Fig. 4) (P<0.05). Oral administration of CoQ10 effectively reduced the IL-6 and TNF-α levels in serum to normal levels and thus minimized inflammation.

**CoQ10 attenuates SCI-induced increases in osteoclastogenesis gene expression in femurs of rats.** The mRNA levels of osteoclast-specific genes RANKL (Fig. 5A) and cathepsin K (Fig. 5B) were increased in femurs of SCI rats. Of note, treatment with CoQ10 significantly decreased the RANKL and cathepsin K mRNA levels in femurs (P<0.05).

**CoQ10 attenuates SCI-induced decreases in osteoblastogenesis gene expression in femurs of rats.** The mRNA levels of the osteoblast-specific gene Cbfa1 (Fig. 6) were decreased in femurs of SCI rats. However, administration of CoQ10 rescued the mRNA levels of Cbfa1 in the femurs of rats following SCI (P<0.05).

**Discussion**

Therapeutic agents including bisphosphonates, estrogen and raloxifene have been implicated in the treatment of bone diseases. However, despite their beneficial effects, they exert certain adverse effects, including thromboembolism and oesophageal irritation (23-25). Therefore, the discovery of novel drugs to treat bone-associated disorders is required. CoQ10 may be a candidate for the prevention of osteoporosis, as it displays cytoprotective properties and acts as an effective free radical scavenger.

The present study explored the efficacy of CoQ10 on bone loss induced by SCI in a murine model. Complete SCI at the lower segment of the thoracic cord of rats is routinely used in pre-clinical studies on the pathogenesis of SCI-induced osteoporosis (8,26,27). It induces severe forms of osteoporosis and an array of factors increasing the susceptibility to osteoporosis, including carrying heavy objects, neural lesions and hormonal imbalance (28). Further direct denervation of bone and indirect alteration of vasoregulation are attributed to SCI-mediated osteoporosis (29). Furthermore, negative imbalance of Ca²⁺ mediated by altered hormone levels is involved in the post-SCI osteoporosis (30). Previous studies on rodents and humans suggested that following SCI, bone resorption is increased due to osteoclast activation (31,32). Morse et al (33) showed that ten days post-SCI, the bone formation rate in rats at the distal femur was significantly lower than that in sham-operated rats. Furthermore, a significant reduction in
the number of osteoclasts was observed in the distal femur five days post-SCI.

It is essential to assess and monitor post-SCI osteoporosis to minimize the prevalence of fracture. BMD and BMC are reliable markers in the assessment of osteoporosis and clearly show the fracture risk in the majority of patients (34). In the present study, rats displayed a significant decrease in BMD and BMC of femur and tibia following SCI as compared with those in the sham group, indicating that tibial and bone loss had occurred. Treatment with CoQ10 restored the BMC and BMD to normal, which may be due to the re-establishment of bone balance through preventing an increase in the number of osteoclasts by inhibiting osteoclast maturation (18).

Reactive oxygen species have a pivotal role in the development of secondary complications following SCI (35). In the present study, SCI rats displayed elevated levels of femoral and tibial MDA with a concomitant decrease in the levels of the antioxidant enzyme SOD. These depleted levels of SOD may have been due to the involvement of SOD in scavenging the free radicals generated by SCI. Thus, these results demonstrated the role of oxidative stress in the progression of osteoporosis following SCI, which is in corroboration with the results of a previous study (36). Treatment with CoQ10 mitigated the oxidative stress and restored the levels of MDA and SOD to normal levels. Thus, the preventive effect of CoQ10 against bone loss may be due to its free radical scavenging properties (37).

Elevated cytokine levels within the bone have been involved in SCI-induced osteoporosis. Demulder et al (38) reported that levels of IL-6 were increased in serum and bone samples of the sternum and iliac crest from patients with SCI. Thus, the elevated cytokines may lead to the recruitment of osteoclasts from marrow precursors and enhance osteoclast activity in bones. In the present study, elevated serum levels of IL-6 were significantly diminished by CoQ10 treatment, which is in corroboration with previous study (39). Furthermore, osteoclasts were highly activated and osteoblasts are suppressed by the inflammatory cytokine TNF-α via the RANKL and osteoprotegerin (OPG) system. In the present study, the elevated serum levels of TNF-α in rats following SCIs were significantly reduced by CoQ10 treatment. Previous studies reported the potential of CoQ10 to decrease TNF-α (40,41). Thus, the anti-osteoporotic effect rendered by CoQ10 may be mediated through an anti-cytokine mechanism.

Previous studies reported increased bone resorption activity post-SCI. RANKL, which is expressed on the surface of bone marrow stromal/osteoblast precursor cells, T cells and B cells, is the prime molecule involved in osteoclast synthesis. RANKLs bind to their cognate receptors, RANK, on osteoclast lineage cells, and are neutralized by the soluble, decoy receptor, OPG, which is also produced by osteoblastic...
lineage cells (42-44). A previous study showed that RANKL mRNA and protein expression in cultured osteoblast-like cells from SCI rats was significantly increased and resulted in increased osteoclastogenesis, thus leading to osteoporosis after SCI (10). In the present study, rats displayed increased mRNA expression of RANKL in the femur following SCI and CoQ10 treatment significantly reversed the altered mRNA expression to normal levels (45).

Cathepsin K is primarily expressed in osteoclasts (46) and has a pivotal role in the degradation of the collagen matrix components of bone (predominantly type-I collagen) at acidic pH. Based on human genetics (47,48), experimental genetics in mice (49), substrate preference and cellular distribution (50), the pivotal role of cathepsin K in osteoclastic bone resorption has been demonstrated. In the present study, rats displayed increased mRNA expression of Cathepsin K in the femur post-SCI. Of note, CoQ10 treatment downregulated cathepsin K in the femurs of rats following SCI and thus prevented the degradation of the bone matrix.

The bone-specific Cbfal gene is a runt-domain-containing transcription factor essential for osteoblastic differentiation and bone formation during embryogenesis and post-natal life (51). Cbfal has two vital functions - promotion of the initial phase of differentiation from mesenchymal stem cells to pre-osteoblasts and inhibition of pre-osteoblast differentiation to mature osteoblasts (52). As expected, in the present study, rats displayed decreased mRNA expression of Cbfal in the femur post-SCI. However, CoQ10 rescued Cbfal mRNA expression and promoted bone matrix production.

In conclusion, treatment with CoQ10 mitigated the bone loss in rats following SCI by increasing BMD and BMC levels, attenuating oxidative stress, debilitating the cytokine levels, depressing RANKL and cathepsin K expression, as well as restoring Cbfal mRNA levels. Thus, CoQ10 may be an effective nutraceutical to ameliorate osteoporosis after SCI. However, further molecular studies are warranted to explore the feasibility of using CoQ10 as an anti-osteoporotic agent.

References


